Evidence map›Paper›PMID 30327606›Full record

ArticleFrontiers in pharmacology2018

Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review.

Luigi Cardia, Gioacchino Calapai, Domenico Quattrone, Cristina Mondello, Vincenzo Arcoraci, Fabrizio Calapai, Carmen Mannucci, Epifanio Mondello

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Pharmacogenomics of Opioid Treatment for Pain Management.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luigi CardiaAnesthesia, Intensive Care and Pain Therapy, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, Messina, Italy.
Gioacchino CalapaiDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, Messina, Italy.
Domenico QuattronePain Therapy Unit, Grande Ospedale Metropolitano Bianchi Melacrino Morelli-Reggio Calabria, Reggio Calabria, Italy.
Cristina MondelloDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, Messina, Italy.
Vincenzo ArcoraciDepartment of Clinical and Experimental Medicine, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, Messina, Italy.
Fabrizio CalapaiPharma.Ca Research Facility (Centro Studi Pharma.Ca), Messina, Italy.
Carmen MannucciDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, Messina, Italy.
Epifanio MondelloAnesthesia, Intensive Care and Pain Therapy, Azienda Ospedaliera Universitaria Policlinico "G. Martino" - Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrocodone is one of the most prescribed oral analgesic drugs and it is one of the most abused drugs in general population. It is a mu-opioid agonist predominantly metabolized to the O-demethylated product hydromorphone and to the N-demethylated product norhydrocodone. The purpose of the study is to summarize the preclinical and clinical characteristics of hydrocodone. Pharmacokinetic aspect (terminal half-life, maximum serum concentration, and time to maximum serum concentration) of hydrocodone and the influence of metabolic genetic polymorphism in analgesic response to hydrocodone are also illustrated and commented. Literature on experimental preclinical pharmacology investigating analgesic activity in laboratory animals is furtherly discussed. Moreover, the authors discuss and comment on the updated data regarding safety profile and effectiveness of hydrocodone in the treatment of chronic pain. A bibliographic research was carried out (from February 01, 2018 to August 28, 2018) independently by two researchers (blinded to the authors and initially on results) in the major scientific databases and research engines of peer-reviewed literature on life sciences and biomedical topics, starting from January 1990 to August 2018. Analysis of results of clinical studies suggests that abuse-deterrent extended-release (ER) hydrocodone formulations can be effective and they are well tolerated in the treatment of chronic low back pain. Weaker is the evidence of the analgesic effectiveness of ER hydrocodone on other chronic pain syndromes and non-cancer non-neuropathic chronic pain. In these conditions, hydrocodone showed to have positive effects in non-controlled open studies and needs to be further studied to assess the real strength of results.

Indexed as

analgesicschronic painhydrocodoneopioidspain

Identifiers

PMID30327606
PMCPMC6174210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.